Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results
Cancer
 
Search Results



Your search returned 1870 record(s).

Page 41 of 187  |  Previous Page   |  Next Page

Cancer Type:   Sort By:

This Search was Made Possible by:


  Survival: Patients: Toxicity: Treatment: Hospital: Country: Date:
401 19.2 months Metastatic colorectal cancer 4 Chemotherapy
Centre René Gauducheau France 4/2014
Treatment Details: Patients: This phase 3 study involved metastatic colorectal cancer patients who were separated into four different groups based on treatment and their genetic status of the KRAS gene. Grou
 
402 19.2 months Metastatic colorecal cancer 4 Chemotherapy
Research Institute and Hospital, National Cancer Center Korea 9/2013
Treatment Details: Patients: This phase 2 study involved 43 metastatic colorectal cancer patients. The median patient age was 54 years and 60.5% were male. Treatment: Patients were treated with the chemo
 
403 19.2 months Metastatic, castration-resistant prostate cancer 5 Chemotherapy
Institut Gustave Roussy, University of Paris Sud France 4/2013
Treatment Details: Patients: This phase 3 study involved metastatic castration-resistant prostate cancer patients who were divided into two separate treatment groups. Group A consisted of 524 male patients w
 
404 19.2 months Metastatic, castration-resistant prostate cancer, bone metastases 4 Biologic therapy
Chemotherapy
Daniel den Hoed Cancer Center Netherlands 11/2012
Treatment Details: Patients: This study involved metastatic castration-resistant prostate cancer patients with metastases to the bone who were divided into two separate treatment groups. There were 301 patie
 
405 19.1 months Metastatic urothelial carcinoma 5 Biologic therapy
Chemotherapy
Indiana University Melvin and Bren Simon Cancer Center United States 4/2011
Treatment Details: Patients: This phase II study involved 43 patients with metastatic urothelial carcinoma who had not received prior chemotherapy. The median patient age was 66 years and 76.7% were male.
 
406 19.1 months Platinum-Resistant Ovarian Cancer 4 Biologic therapy
Chemotherapy
Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione GPascale IRCCS Italy 4/2015
Treatment Details: Patients: This phase 2 study involved platinum-resistant or platinum-refractory ovarian cancer patients who had received prior chemotherapy. Patients were divided into two separate treatme
 
407 19.1 months Metastatic triple-negative breast cancer 4 Chemotherapy
Fudan University Shanghai Cancer Center China 1/2015
Treatment Details: Patients: This phase 2 study involved 64 female metastatic triple-negative breast cancer patients (negative for estrogen receptor, progesterone receptor, and HER2 genetic cancer markers).
 
408 19.1 months Metastatic Breast Cancer 4 Biologic therapy
Chemotherapy
Dicle University School of Medicine Turkey 11/2014
Treatment Details: Patients: This study involved 46 previously treated HER2-positive metastatic breast cancer patients who had brain metastasis. The median patient age at the time of diagnosis was 45 years.
 
409 19.1 months Metastatic breast cancer 5 Chemotherapy
Indiana University Medical Center United States 2/2003
Treatment Details: Patients: This Phase III trial involved 731 patients with metastatic breast cancer. Patients were divided into three groups: Group A contained 245 patients, Group B contained 242 patients,
 
410 19.0 months Hormone refractory prostate cancer 3 Biologic therapy
Warren Grant Magnuson Clinical Center, NIH United States 3/2005
Treatment Details: Patients: This Phase II study involved 72 men with hormone refractory malignant prostate cancer with bone metastases. The patients were randomly divided into two groups. Group A had 36 pat
 
Page 41 of 187  | Previous Page  | Next Page